Atypical chronic myeloid leukemia, BCR-ABL1 negative

MONDO:0004653

A myelodysplastic/myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene. (WHO, 2001)

Also known as: aCML, atypical CML, atypical chronic myeloid leukaemia, atypical chronic myeloid leukemia, atypical chronic myeloid leukemia, BCR-ABL1 Negative, subacute granulocytic leukaemia, subacute granulocytic leukemia, subacute myelogenous leukaemia

3096 clinical trials for this condition and its sub-types, 17 tagged with Atypical chronic myeloid leukemia, BCR-ABL1 negative itself.

Follow this condition to get notified about new trials

Where it sits in the disease tree

Browse by category →

Part of

↑ Myeloid leukemia (1334) ↑ Myelodysplastic/myeloproliferative neoplasm (234) ↑ Myelodysplastic/myeloproliferative disease (206)

Including sub-types (3096) Tagged with Atypical chronic myeloid leukemia, BCR-ABL1 negative (17)

Trials to join now! 8 Not yet recruiting 1 Not yet finished but already full! 6 Completed 2

New hope for rare blood cancers: interferon trial launches

Disease control Not yet recruiting

This phase 2 trial tests ropeginterferon alfa-2b, a long-acting immune protein, in 35 adults with rare blood cancers like CMML and MDS/MPN overlap syndromes. The drug aims to slow cancer cell growth by boosting the immune system. Researchers will check safety, best dose, and how …

Phase 2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control

Last updated Jun 27, 2026 12:29 UTC

Atypical chronic myeloid leukemia, BCR-ABL1 negative

Where it sits in the disease tree

New hope for rare blood cancers: interferon trial launches